{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:08:09Z","timestamp":1772928489170,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-026-05835-0","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:56:35Z","timestamp":1770231395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Do we need to treat dialysis patients differently? Infliximab therapy in a patient with ulcerative colitis on hemodialysis: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-4024","authenticated-orcid":false,"given":"Fruzsina","family":"Balogh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0900-1966","authenticated-orcid":false,"given":"Dorottya","family":"Angyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8819-6460","authenticated-orcid":false,"given":"Lorant","family":"Gonczi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6087-7398","authenticated-orcid":false,"given":"Livia","family":"Lontai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-6488","authenticated-orcid":false,"given":"Peter L.","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9865-2642","authenticated-orcid":false,"given":"Akos","family":"Ilias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"5835_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.crohns.2010.08.004","volume":"5","author":"PL Lakatos","year":"2011","unstructured":"Lakatos PL, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977\u20132008. J Crohns Colitis. 2011;5:5\u201313. https:\/\/doi.org\/10.1016\/j.crohns.2010.08.004.","journal-title":"J Crohns Colitis"},{"key":"5835_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S2468-1253(22)00358-2","volume":"8","author":"S Singh","year":"2023","unstructured":"Singh S, Boland BS, Jess T, Moore AA. Management of inflammatory bowel diseases in older adults. Lancet Gastroenterol Hepatol. 2023;8:368\u201382. https:\/\/doi.org\/10.1016\/S2468-1253(22)00358-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"5835_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030686","volume":"11","author":"PA Golovics","year":"2022","unstructured":"Golovics PA, Verdon C, Wetwittayakhlang P, Filliter C, Gonczi L, Hahn GD, et al. Increased prevalence of myocardial infarction and stable stroke proportions in patients with inflammatory bowel diseases in Quebec in 1996-2015. J Clin Med. 2022;11: 686. https:\/\/doi.org\/10.3390\/jcm11030686.","journal-title":"J Clin Med"},{"key":"5835_CR4","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/ecco-jcc\/jjw054","volume":"10","author":"AN Ananthakrishnan","year":"2016","unstructured":"Ananthakrishnan AN, Shi HY, Tang W, et al. Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis. 2016;10:1224\u201336.","journal-title":"J Crohns Colitis"},{"key":"5835_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/MOG.0000000000000536","volume":"35","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol. 2019;35:302\u201310. https:\/\/doi.org\/10.1097\/MOG.0000000000000536.","journal-title":"Curr Opin Gastroenterol"},{"key":"5835_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/gastro\/goz041","volume":"8","author":"P Shashi","year":"2019","unstructured":"Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. Gastroenterol Rep. 2019;8:306\u201311.","journal-title":"Gastroenterol Rep"},{"key":"5835_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154422","volume":"11","author":"GD Hahn","year":"2022","unstructured":"Hahn GD, Golovics PA, Wetwittayakhlang P, et al. Safety of biological therapies in elderly inflammatory bowel diseases: a systematic review and meta-analysis. J Clin Med. 2022;11: 4422.","journal-title":"J Clin Med"},{"key":"5835_CR8","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","volume":"128","author":"G J\u00e4rnerot","year":"2005","unstructured":"J\u00e4rnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomised, placebo-controlled study. Gastroenterology. 2005;128:1805\u201311.","journal-title":"Gastroenterology"},{"key":"5835_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis. 2023;82:119\u201329.","journal-title":"Ann Rheum Dis"},{"key":"5835_CR10","unstructured":"European Medicines Agency. Xeljanz: EPAR\u2013product information. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf. Accessed 6 Dec 2025."},{"key":"5835_CR11","unstructured":"European Medicines Agency. Zessly: EPAR\u2013product information. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zessly-epar-product-information_en.pdf. Accessed 5 Apr 2024."},{"key":"5835_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/138920021503140412212905","volume":"15","author":"S Shi","year":"2014","unstructured":"Shi S. Biologics: an update and challenge of their pharmacokinetics. Curr Drug Metab. 2014;15:271\u201390.","journal-title":"Curr Drug Metab"},{"key":"5835_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.5414\/CPP48297","volume":"48","author":"AA Fasanmade","year":"2010","unstructured":"Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48:297\u2013308.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"5835_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","volume":"149","author":"JF Brandse","year":"2015","unstructured":"Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350\u20135.","journal-title":"Gastroenterology"},{"key":"5835_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000054","volume":"93","author":"M Chiba","year":"2014","unstructured":"Chiba M, Tsuda S, Tsuji T, Nakane K, Komatsu M, Miura Y, et al. Crohn\u2019s disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature. Medicine (Baltimore). 2014;93: e54.","journal-title":"Medicine (Baltimore)"},{"key":"5835_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1684\/ejd.2017.3064","volume":"27","author":"M Larquey","year":"2017","unstructured":"Larquey M, Girard C, Sbidian E, Richard MA, Aubin F, Schmutz JL. Efficacy of biologics in psoriasis patients under hemodialysis. Eur J Dermatol. 2017;27:531\u20133.","journal-title":"Eur J Dermatol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-05835-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-05835-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-05835-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:30:51Z","timestamp":1772857851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-05835-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5835"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-05835-0","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report. Written informed consent was obtained from participants (or their parents\/legal guardians\/next-of-kin) for publication of the details of their medical case and any accompanying images. Ethical approval is not required for this study in accordance with local or national guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PLL has been a speaker and\/or advisory board member: AbbVie, Amgen, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Gilead, Janssen, Eli Lilly, Merck, Organon, Pendopharm, Pfizer, Roche, Sandoz, and Takeda and has received unrestricted research grants from AbbVie, Gilead, and Pfizer. AI has been a speaker for Janssen and AbbVie. All remaining authors have no further competing of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}